Based on the Amphastar P stock forecast from 2 analysts, the average analyst target price for Amphastar P is USD 41.00 over the next 12 months. Amphastar P’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Amphastar P is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Amphastar P’s stock price was USD 23.56. Amphastar P’s stock price has changed by +2.48% over the past week, -16.72% over the past month and -42.41% over the last year.
No recent analyst target price found for Amphastar P
No recent average analyst rating found for Amphastar P
Company Overview Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Read Less
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe ...Read More
Frequently Asked Questions About Amphastar P (AMPH) Stock
Based on ratings from 2 analysts Amphastar P's stock is Hold . Stock Target Advisor's fundamental analysis is Bullish . The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AMPH's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMPH is USD 41.00 over the next 12 months. The maximum analyst target price is USD 55 while the minimum anlayst target price is USD 32.
AMPH stock's Price/Earning ratio is 9.29.
Our analysis grades AMPH stock's Price / Earning ratio at D. This means that AMPH stock's Price/Earning ratio is above 35% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this AMPH may be fairly valued for its sector
The last closing price of AMPH's stock was USD 23.56.
The most recent market capitalization for AMPH is USD 1.35B.
Based on targets from 2 analysts, the average taret price for AMPH is projected at USD 41.00 over the next 12 months.
This means that AMPH's stock price may go up by +74.02% over the next 12 months.
We can't find any ETFs which contains Amphastar P's stock.
As per our most recent records Amphastar P has 2,028 Employees.
Amphastar P's registered address is 11570 6th Street, Rancho Cucamonga, CA, United States, 91730.
You can get more information about it from Amphastar P's website at https://www.amphastar.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Amphastar P (AMPH) Stock
Based on ratings from 2 analysts Amphastar P's stock is Hold . Stock Target Advisor's fundamental analysis is Bullish . The stock has buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AMPH's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AMPH is USD 41.00 over the next 12 months. The maximum analyst target price is USD 55 while the minimum anlayst target price is USD 32.
AMPH stock's Price/Earning ratio is 9.29.
Our analysis grades AMPH stock's Price / Earning ratio at D. This means that AMPH stock's Price/Earning ratio is above 35% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this AMPH may be fairly valued for its sector
The last closing price of AMPH's stock was USD 23.56.
The most recent market capitalization for AMPH is USD 1.35B.
Based on targets from 2 analysts, the average taret price for AMPH is projected at USD 41.00 over the next 12 months.
This means that AMPH's stock price may go up by +74.02% over the next 12 months.
We can't find any ETFs which contains Amphastar P's stock.
As per our most recent records Amphastar P has 2,028 Employees.
Amphastar P's registered address is 11570 6th Street, Rancho Cucamonga, CA, United States, 91730.
You can get more information about it from Amphastar P's website at https://www.amphastar.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
